6 Results for "

wild-type HepG2 cells

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "wild-type HepG2 cells" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-N0309
CAS No.: 114590-20-4
Soyasaponin Ba is a soyasaponin that can be isolated from Phaseolus vulgaris, acts as an aldose reductase inhibitor (ARI). Soyasaponin Ba activates Akt/GSK3β/β-catenin signaling pathway, reduces lipid accumulation, lowers ROS generation, improves mitochondrial membrane potential, ATP levels, and morphology, and inhibits apoptosis. Soyasaponin Ba can be used for the research of lipid accumulation and secondary diabetic complications .
loading...
    loading...
Cat. No.: HY-161067
Target:  

EGFR Apoptosis

Research Areas:  

Cancer

EGFR-IN-96 (compound 7a) is a thieno[2,3-d]pyrimidine EGFR inhibitor that can induce apoptosis. EGFR-IN-96 arrests the growth of HepG2 cells in the S phase and G2/M phase, and inhibits the growth of cancer cells bearing EGFR wild-type and EGFR T790M .
loading...
    loading...
Cat. No.: HY-N7484
CAS No.: 545-84-6
(−)-Voacangarine is an indole alkaloid, which exhibits cytotoxic effects against cancer cells HepG2, A375, MDA-MB-231, SH-SY5Y, and CT26 with IC50 of 5~20 mg/mL. (−)-Voacangarine inhibits the cultivation of Saccharomyces cerevisiae wildtype and repair-deficient mutants .
loading...
    loading...
Cat. No.: HY-164031
CAS No.: 4052-13-5
Target:  

Cytochrome P450

Research Areas:  

Neurological Disease

Cloperidone acts as an inhibitor and substrate of CYP2C9, with an IC50 of 17.7 μM. Cloperidone exhibits enhanced cytotoxicity in cells expressing CYP2C9. It can be used in the research of sedative/hypnotic-related diseases .
loading...
    loading...
Cat. No.: HY-164031A
CAS No.: 525-26-8
Target:  

Cytochrome P450

Research Areas:  

Neurological Disease

Cloperidone hydrochloride acts as an inhibitor and substrate of CYP2C9, with an IC50 of 17.7 μM. Cloperidone hydrochloride exhibits enhanced cytotoxicity in cells expressing CYP2C9. It can be used in the research of sedative/hypnotic-related diseases .
loading...
    loading...
Cat. No.: HY-183667
CAS No.: 1332390-06-3
Research Areas:  

Cancer

JNJ-pan-AR is an orally active androgen receptor (AR) inhibitor with an IC50 of 19 nM and a Ki of 8.4 nM against human wild-type AR. JNJ-pan-AR abolishes androgen-induced KLK2 and KLK3 mRNA expression and reduces androgen-dependent colony formation in prostate cancer cells. JNJ-pan-AR blocks AR nuclear translocation, inhibits PSA protein expression, and represses the growth of AR-dependent tumor cells and ARF877L-driven tumor xenografts. JNJ-pan-AR blocks transactivation and signaling of wild-type AR and various mutant AR variants. JNJ-pan-AR is applicable for research on castration-resistant prostate cancer .
loading...
    loading...